Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma

Amy Skorupa, Matthew Beldner, Andrew Kraft, Alberto J. Montero

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.

Original languageEnglish (US)
Pages (from-to)1015-1017
Number of pages3
JournalCancer Biology and Therapy
Issue number7
StatePublished - Jul 2007


  • Ecteinascidin-743 (Yondelis)
  • Rhabdomyolysis
  • Sarcoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma'. Together they form a unique fingerprint.

Cite this